Log in

Relevant bibliographies by topics / BRAF35

Contents

Journal articles

Academic literature on the topic 'BRAF35'

Author: Grafiati

Published: 1 April 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'BRAF35.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "BRAF35"

1

Rugerio-Martínez, Claudia Ivette, Daniel Ramos, Abel Segura-Olvera, et al. "Dp71 Point Mutations Induce Protein Aggregation, Loss of Nuclear Lamina Integrity and Impaired Braf35 and Ibraf Function in Neuronal Cells." International Journal of Molecular Sciences 23, no. 19 (2022): 11876. http://dx.doi.org/10.3390/ijms231911876.

Full text

Abstract:

Dystrophin Dp71 is the most abundant product of the Duchenne muscular dystrophy gene in the nervous system, and mutations impairing its function have been associated with the neurodevelopmental symptoms present in a third of DMD patients. Dp71 is required for the clustering of neurotransmitter receptors and the neuronal differentiation of cultured cells; nonetheless, its precise role in neuronal cells remains to be poorly understood. In this study, we analyzed the effect of two pathogenic DMD gene point mutations on the Dp71 function in neurons. We engineered C272Y and E299del mutations to exp

APA, Harvard, Vancouver, ISO, and other styles

2

Mi LEE, Young, and Wankee KIM. "Association of human kinesin superfamily protein member 4 with BRCA2-associated factor 35." Biochemical Journal 374, no. 2 (2003): 497–503. http://dx.doi.org/10.1042/bj20030452.

Full text

Abstract:

A large portion of human kinesin superfamily protein member 4 (KIF4) is associated with the nuclear matrix during the interphase, while a small portion is found in the cytoplasm. During mitosis, it is associated with chromosomes throughout the entire process. In the present study, we identified a protein that interacts with KIF4 using a yeast two-hybrid system, co-immunoprecipitation and co-fractionation. This protein is BRCA2-associated factor 35 (BRAF35) containing a non-specific DNA binding high-mobility-group domain and a kinesin-like coiled-coil domain. It appeared that the interaction be

APA, Harvard, Vancouver, ISO, and other styles

3

Hakimi, M. A., D. A. Bochar, J. Chenoweth, W. S. Lane, G. Mandel, and R. Shiekhattar. "A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes." Proceedings of the National Academy of Sciences 99, no. 11 (2002): 7420–25. http://dx.doi.org/10.1073/pnas.112008599.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Zanchetta, Melania E., Luisa M. R. Napolitano, Danilo Maddalo, and Germana Meroni. "The E3 ubiquitin ligase MID1/TRIM18 promotes atypical ubiquitination of the BRCA2-associated factor 35, BRAF35." Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1864, no. 10 (2017): 1844–54. http://dx.doi.org/10.1016/j.bbamcr.2017.07.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ceballos-Chavez, M., S. Rivero, P. Garcia-Gutierrez, et al. "Control of neuronal differentiation by sumoylation of BRAF35, a subunit of the LSD1-CoREST histone demethylase complex." Proceedings of the National Academy of Sciences 109, no. 21 (2012): 8085–90. http://dx.doi.org/10.1073/pnas.1121522109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lee, Belinda, Angelyn Anton, Margaret Lee, et al. "Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC)." Journal of Clinical Oncology 35, no. 4_suppl (2017): 728. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.728.

Full text

Abstract:

728 Background: BRAF mutated (BRAFm) CRC represents ~10% of all CRC and is associated with significantly poorer prognosis. However, responses to chemotherapy do still occur. Some data suggest that the poor prognosis associated with BRAFm CRC is dominated by substantially poorer second line PFS (PFS2), whereas first line PFS (PFS1) was similar for both BRAFm and BRAF wildtype (BRAFwt) CRC. Using a large multicenter dataset, our study aimed to examine PFS1 and PFS2 in BRAFm versus BRAFwt CRC. Methods: Prospectively collected data from the Treatment of Recurrent and Advanced Colorectal Cancer (TR

APA, Harvard, Vancouver, ISO, and other styles

7

Osterlund, Pia J., Emerik Osterlund, Aki Uutela, et al. "Resectability, conversion and resections rates, and outcomes in RAS&BRAF wildtype (wt), RAS mutant (mt) and BRAFmt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study." Journal of Clinical Oncology 39, no. 15_suppl (2021): 3532. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3532.

Full text

Abstract:

3532 Background: Outcomes of metastasectomy varies with RAS and BRAF-status, but the effect on resectability, conversion and resection rates has not been extensively studied. Methods: The prospective Finnish RAXO study (NCT01531621) included 1086 patients 2011-2018 (Osterlund et al TLRHE 2021, Isoniemi et al BJS 2021) of which 906 were included in this secondary endpoint analysis. Excluded had missing KRAS/ NRAS/ BRAF-V600E test, were untreatable or had an atypical BRAF mutation. We studied repeated centralized resectability assessment, conversion and resectability rates in mCRC, and overall s

APA, Harvard, Vancouver, ISO, and other styles

8

Braithwaite, Matthew, Christopher Duane Nevala-Plagemann, Kelsey Baron, Benjamin Haaland, Lisa M. Pappas, and Ignacio Garrido-Laguna. "Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States." Journal of Clinical Oncology 38, no. 15_suppl (2020): 4030. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4030.

Full text

Abstract:

4030 Background: BRAF mutations portend a poor prognosis in metastatic colorectal cancer (mCRC). Recent trials have hypothesized that using more aggressive triplet-based chemotherapy regimens such as FOLFOXIRI in the frontline setting may improve outcomes in this patient population. In this study, we utilized real-world data to assess whether FOLFOXIRI is being used in the United States (US) and compared survival outcomes in BRAF mutated (BRAFmt) mCRC stratified by first line (1L) therapy. Methods: The nationwide Flatiron Health EHR-derived de-identified database was reviewed for patients diag

APA, Harvard, Vancouver, ISO, and other styles

9

Hernandez-Aya, Leonel Fernando, Matthew Burke, Jenna M. Collins, et al. "Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy." Journal of Clinical Oncology 38, no. 15_suppl (2020): e22036-e22036. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22036.

Full text

Abstract:

e22036 Background: Despite the success of anti-programmed cell death-1 (PD-1) based therapies that prolong survival in advanced melanoma, some patients experience disease progression. Real-world treatment patterns and outcomes after progression on anti-PD-1 based regimens are unknown. Methods: Adults with advanced melanoma and a record of disease progression on anti-PD-1 treatment (alone or in combination) between 1 Sept 2014–31 Jan 2019 were selected from the Flatiron Health Oncology electronic medical record (EMR) database for this retrospective study. Index progression date was defined as a

APA, Harvard, Vancouver, ISO, and other styles

10

Trunk, Andrew, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna. "Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States." Journal of the National Comprehensive Cancer Network 20, no. 2 (2022): 144–50. http://dx.doi.org/10.6004/jnccn.2021.7059.

Full text

Abstract:

Background: BRAF mutations portend a poor prognosis in metastatic colorectal cancer (mCRC). Whether these patients may benefit from more aggressive frontline chemotherapy with a triplet regimen such as FOLFOXIRI remains unclear. We used real-world data from a cohort of patients in the United States to assess the BRAF testing rate, determine the prevalence of FOLFOXIRI use, and compare survival outcomes in mCRC, stratified by BRAF mutation status and first-line therapy. Methods: A nationwide electronic health record–derived deidentified database was reviewed for patients diagnosed with mCRC bet

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!